AU2001218841A1 - Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase - Google Patents
Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipaseInfo
- Publication number
- AU2001218841A1 AU2001218841A1 AU2001218841A AU1884101A AU2001218841A1 AU 2001218841 A1 AU2001218841 A1 AU 2001218841A1 AU 2001218841 A AU2001218841 A AU 2001218841A AU 1884101 A AU1884101 A AU 1884101A AU 2001218841 A1 AU2001218841 A1 AU 2001218841A1
- Authority
- AU
- Australia
- Prior art keywords
- modulators
- derivatives
- glycerophosphoinositol
- cytosolic
- phospholipase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002326 glycerophosphoinositols Chemical class 0.000 title abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title 1
- 102000015439 Phospholipases Human genes 0.000 title 1
- 108010064785 Phospholipases Proteins 0.000 title 1
- 230000001086 cytosolic effect Effects 0.000 title 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 abstract 1
- 108020002496 Lysophospholipase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
Abstract
Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R'1, R'2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2000/000447 WO2002038575A1 (en) | 2000-11-07 | 2000-11-07 | Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001218841A1 true AU2001218841A1 (en) | 2002-05-21 |
Family
ID=11133577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001218841A Abandoned AU2001218841A1 (en) | 2000-11-07 | 2000-11-07 | Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase |
Country Status (11)
Country | Link |
---|---|
US (1) | US7625883B1 (en) |
EP (1) | EP1332149B1 (en) |
JP (1) | JP2004513176A (en) |
CN (1) | CN1300155C (en) |
AT (1) | ATE308548T1 (en) |
AU (1) | AU2001218841A1 (en) |
CA (1) | CA2427352C (en) |
DE (1) | DE60023758T2 (en) |
ES (1) | ES2252079T3 (en) |
IL (2) | IL155619A0 (en) |
WO (1) | WO2002038575A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPS282602A0 (en) * | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
WO2006006161A2 (en) * | 2004-07-09 | 2006-01-19 | Vascular Biogenics Ltd. | Improved process for the preparation of oxidized phospholipids |
GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
CN101505763A (en) * | 2006-06-09 | 2009-08-12 | 鹿特丹伊拉斯姆斯大学医疗中心 | Modulation of the immune system by inositol phospholipids |
BRPI0807972A2 (en) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | PHARMACEUTICAL COMPOSITIONS UNDERSTANDING 3,5-DIAMINO-6- (2,3-DICHLOPHENYL) -L, 2,4-TRIAZINE OR R (-) - 2,4-DIAMINO-5- (2,3-DICHLOROPHENYL) -6- FLUOROMETILPIRIM IDINA AND ONE NK1 |
CN101951921A (en) * | 2007-09-17 | 2011-01-19 | 比奥尼里斯有限责任公司 | Be used for the treatment of cachectic ways and means |
JP5420848B2 (en) * | 2008-02-28 | 2014-02-19 | 株式会社コーセー | Whitening agent and skin external preparation for whitening |
JP2009269851A (en) * | 2008-05-07 | 2009-11-19 | Nikko Chemical Co Ltd | Inhibitor of prostaglandin e2 production and its utilization |
WO2012158591A1 (en) * | 2011-05-18 | 2012-11-22 | The Research Foundation Of State University Of New York | Anti-blepharitis products and methods |
JP5670858B2 (en) * | 2011-10-14 | 2015-02-18 | イ.エルレ.ビ.イスティトゥト ディ リチェルケ ビオテクノロジケ ソチエタ ペル アツィオニ | Glycerophosphoinositol derivatives as modulators of cytosolic phospholipases |
ITRM20120473A1 (en) * | 2012-10-04 | 2014-04-05 | Consiglio Nazionale Ricerche | USE OF GLYCEROPHOSPHOINOSITOLS FOR THE TREATMENT OF SEPTIC SHOCK |
JP5701371B2 (en) | 2012-12-28 | 2015-04-15 | 花王株式会社 | Sphingomyelin containing supplements |
RU2580280C2 (en) * | 2014-07-08 | 2016-04-10 | Общество с ограниченной ответственностью "НИТРОЗДРАВ" | Composition for local application for reduction or relief of pain syndrome |
KR20170086019A (en) * | 2014-09-24 | 2017-07-25 | 이스티튜토 프로필라티코 이 파르마씨유티코 칸디올리 & 씨. 에스.피.에이. | Compositions useful for the prevention and/or treatment of infections and inflammations |
CN104447856A (en) * | 2014-12-11 | 2015-03-25 | 河南省农科院农副产品加工研究所 | Preparation method of glycerol phosphatidylinositol |
IT202200010199A1 (en) * | 2022-05-17 | 2023-11-17 | Plantarei Biotech S R L | GLYCEROPHOSPHOINOSITOL IN THE PREVENTION AND TREATMENT OF COVID-19 INFECTIONS AND METHOD FOR ITS OBTAINMENT |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2659048A1 (en) * | 1976-12-27 | 1978-07-06 | Nattermann A & Cie | Inositol phosphatide ester derivs. - with antilipaemic, anti-atherosclerotic, platelet aggregation reducing and peripheral blood flow increasing activity |
FR2517310A1 (en) | 1981-11-27 | 1983-06-03 | Unilever Nv | Salts of alpha glycero phosphatide ester(s) - skin treatment agents to reduce dryness and peeling |
US4585762A (en) | 1982-07-30 | 1986-04-29 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same |
US4997761A (en) * | 1987-10-06 | 1991-03-05 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
IT1239474B (en) | 1989-10-27 | 1993-11-02 | Depha Team Srl | PHARMACEUTICAL COMPOSITIONS BASED ON L-ALPHA-GLYCEROPHOSPHORYL-D-MYO- INOXITOL OR ITS ALKALINE OR ALKALINE-EARTH SALTS FOR THERAPY OF PERIPHERAL NEROPATHIES OF DYSMETABOLIC OR TOXIC ORIGIN, AND FUNCTIONAL ORBANIC BASE |
IT1238683B (en) * | 1990-02-09 | 1993-09-01 | Istituto Chemioterapico | PROCEDURE FOR THE PREPARATION OF L-A-GLYCYLPHOSFORIL-D-MYOINOSITOL AND ITS SALTS FROM RAW OR PARTIALLY PURIFIED PHOSPHATIDES |
IT1247093B (en) | 1991-01-22 | 1994-12-12 | Flarer S R L Ora Castellini S | SALINE DERIVATIVES OF GLYCERYL PHOSPHORYL MYINOSITOL FOR THERAPEUTIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
US5464754A (en) | 1993-08-17 | 1995-11-07 | The Regents Of The University Of California | Assay and substrate for arachidonoyl-specific phospholipase A2 |
US5478857A (en) * | 1993-12-23 | 1995-12-26 | Eli Lilly And Company | Use of PLA2 inhibitors as treatment for alzheimer's disease |
DE19623950A1 (en) | 1996-06-15 | 1997-12-18 | Boehringer Ingelheim Kg | Pharmaceutical preparation in the form of liposomes |
US6801860B1 (en) * | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
SE532388C2 (en) * | 2008-03-14 | 2010-01-12 | Tetra Laval Holdings & Finance | Packaging laminates and containers with two separate gas barrier layers and method for their preparation |
-
2000
- 2000-11-07 CN CNB008200076A patent/CN1300155C/en not_active Expired - Lifetime
- 2000-11-07 AU AU2001218841A patent/AU2001218841A1/en not_active Abandoned
- 2000-11-07 IL IL15561900A patent/IL155619A0/en unknown
- 2000-11-07 ES ES00981612T patent/ES2252079T3/en not_active Expired - Lifetime
- 2000-11-07 AT AT00981612T patent/ATE308548T1/en not_active IP Right Cessation
- 2000-11-07 US US10/415,881 patent/US7625883B1/en not_active Expired - Lifetime
- 2000-11-07 EP EP00981612A patent/EP1332149B1/en not_active Expired - Lifetime
- 2000-11-07 JP JP2002541107A patent/JP2004513176A/en not_active Withdrawn
- 2000-11-07 CA CA2427352A patent/CA2427352C/en not_active Expired - Lifetime
- 2000-11-07 DE DE60023758T patent/DE60023758T2/en not_active Expired - Lifetime
- 2000-11-07 WO PCT/IT2000/000447 patent/WO2002038575A1/en active IP Right Grant
-
2003
- 2003-04-28 IL IL155619A patent/IL155619A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2427352A1 (en) | 2002-05-16 |
CN1455779A (en) | 2003-11-12 |
CN1300155C (en) | 2007-02-14 |
JP2004513176A (en) | 2004-04-30 |
WO2002038575A1 (en) | 2002-05-16 |
DE60023758D1 (en) | 2005-12-08 |
ES2252079T3 (en) | 2006-05-16 |
EP1332149A1 (en) | 2003-08-06 |
IL155619A (en) | 2010-06-30 |
DE60023758T2 (en) | 2006-12-07 |
EP1332149B1 (en) | 2005-11-02 |
IL155619A0 (en) | 2003-11-23 |
CA2427352C (en) | 2010-10-12 |
US7625883B1 (en) | 2009-12-01 |
ATE308548T1 (en) | 2005-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001218841A1 (en) | Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase | |
AP9901534A0 (en) | Pharmaceutical formulations. | |
DK1109812T3 (en) | pyrrolobenzodiazepines | |
MXPA02009706A (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts. | |
AU6613896A (en) | Chemical compounds | |
ES2114487B1 (en) | SYNERGISTIC STABILIZING MIX. | |
USD454585S1 (en) | Watch writing instrument | |
DE69918122D1 (en) | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS THROUGH SPECIAL USE OF ANTIOXIDANE | |
AU2001296819A1 (en) | Nanoscale piezoelectric generation systems background of the invention | |
DK0750631T3 (en) | Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo [c] azepine-3-ondisulfide derivatives as enkephalinase and ACE inhibitors | |
BR0011030A (en) | Compositions of substantially oil-free cycloporin | |
WO1999032509A3 (en) | Hemiasterlin analogs | |
HK1045990A1 (en) | Novel derivatives and analogues of galanthamin. | |
BR0114379A (en) | Substituted c-cyclohexylmethylamine derivatives | |
BR9915692A (en) | Eletriptan hydrobromide monohydrate | |
BG106316A (en) | Ambroxol-containing lozenge | |
AU2881399A (en) | N1-modified glycopeptides | |
BR9812085A (en) | "method for the synthesis of quinoline derivatives" | |
BR0114380A (en) | 1-Aminobutan-3-ol-substituted derivatives | |
UY26574A1 (en) | "PROCEDURE FOR THE ENZYMATIC SEPARATION OF RACEMATES OF AMINOMETIL-ARYL-CYCLOHEXANOL DERIVATIVES". | |
MXPA03008837A (en) | A stable pharmaceutical composition of pravastatin. | |
CA2388830A1 (en) | Oral solution containing galanthamine and a sweetening agent | |
USD444502S1 (en) | Holder for a writing instrument | |
USD370417S (en) | Clock case | |
AU2001256406A1 (en) | Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity |